Immunobiology of Transplantation: Impact on Targets for Large and Small Molecules
Organ transplantation is the preferred method of treatment for many forms of end‐stage organ failure. However, immunosuppressive drugs that are used to avoid rejection can result in numerous undesirable effects (infection, malignancy, hypertension, diabetes, and accelerated arteriosclerosis). Moreov...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2011-08, Vol.90 (2), p.229-242 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 242 |
|---|---|
| container_issue | 2 |
| container_start_page | 229 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 90 |
| creator | Azimzadeh, AM Lees, JR Ding, Y Bromberg, JS |
| description | Organ transplantation is the preferred method of treatment for many forms of end‐stage organ failure. However, immunosuppressive drugs that are used to avoid rejection can result in numerous undesirable effects (infection, malignancy, hypertension, diabetes, and accelerated arteriosclerosis). Moreover, they are not effective at preventing chronic rejection resulting in late graft loss. This review summarizes the fundamental concepts underlying the rejection of solid‐organ allografts with the aim of highlighting potential new targets for therapeutics. Future improvement will depend on new therapeutic moieties, including biologics, to target various pathways of both the innate and adaptive arms of immunity. Results from some of the most recent clinical trials in transplantation and emerging new therapies are also discussed.
Clinical Pharmacology & Therapeutics (2011) 90 2, 229–242. doi:10.1038/clpt.2011.106 |
| doi_str_mv | 10.1038/clpt.2011.106 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_888092318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>888092318</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3986-a661a221028fad8604d8192ce9062766bfd8ae910e9fe8ed1c684d91b3e14fa63</originalsourceid><addsrcrecordid>eNp9kE1P3DAYhK2KCpaPY6-VOSBOAdvJeu3e0AroSlsBanqO3nVeo1ROnNqJ0P77OspCbz3ZIz0zHg8hXzi74SxXt8b1w41gnCcpP5EFX-Yik8t8eUQWjDGdaZHLE3Ia4-8kC63UMTkRfMWlWMkFedm07dj5XeOdf91Tb2kZoIu9g26AofHdN7ppezAD9R0tIbziEKn1gW6nO4Wupj9bcI7-8A7N6DCek88WXMSLw3lGfj3cl-vv2fbpcbO-22Ym10pmICUHITgTykKtJCtqxbUwqNnUTO5srQA1Z6gtKqy5kaqoNd_lyAsLMj8j13NuH_yfEeNQtU006FJz9GOslFIs_Z2rRGYzaYKPMaCt-tC0EPYVZ9U0YjWNWE0jJjklfz0kj7sW6w_6fbUEXB0AiAacTYuZJv7jioKtZJEnTs_cW-Nw__9Xq_Vzud4-l5OeS1zO3g6GMeCHeTK9M38Bbz-W-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>888092318</pqid></control><display><type>article</type><title>Immunobiology of Transplantation: Impact on Targets for Large and Small Molecules</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Azimzadeh, AM ; Lees, JR ; Ding, Y ; Bromberg, JS</creator><creatorcontrib>Azimzadeh, AM ; Lees, JR ; Ding, Y ; Bromberg, JS</creatorcontrib><description>Organ transplantation is the preferred method of treatment for many forms of end‐stage organ failure. However, immunosuppressive drugs that are used to avoid rejection can result in numerous undesirable effects (infection, malignancy, hypertension, diabetes, and accelerated arteriosclerosis). Moreover, they are not effective at preventing chronic rejection resulting in late graft loss. This review summarizes the fundamental concepts underlying the rejection of solid‐organ allografts with the aim of highlighting potential new targets for therapeutics. Future improvement will depend on new therapeutic moieties, including biologics, to target various pathways of both the innate and adaptive arms of immunity. Results from some of the most recent clinical trials in transplantation and emerging new therapies are also discussed.
Clinical Pharmacology & Therapeutics (2011) 90 2, 229–242. doi:10.1038/clpt.2011.106</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/clpt.2011.106</identifier><identifier>PMID: 21716276</identifier><identifier>CODEN: CLPTAT</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Adaptive Immunity ; Animals ; Biological and medical sciences ; Drug Delivery Systems ; Drug Design ; Graft Rejection - immunology ; Graft Rejection - prevention & control ; Graft Survival - drug effects ; Graft Survival - immunology ; Humans ; Immunity, Innate ; Immunosuppressive Agents - pharmacology ; Medical sciences ; Organ Transplantation - methods ; Pharmacology. Drug treatments</subject><ispartof>Clinical pharmacology and therapeutics, 2011-08, Vol.90 (2), p.229-242</ispartof><rights>2011 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3986-a661a221028fad8604d8192ce9062766bfd8ae910e9fe8ed1c684d91b3e14fa63</citedby><cites>FETCH-LOGICAL-c3986-a661a221028fad8604d8192ce9062766bfd8ae910e9fe8ed1c684d91b3e14fa63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1038%2Fclpt.2011.106$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1038%2Fclpt.2011.106$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24407643$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21716276$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Azimzadeh, AM</creatorcontrib><creatorcontrib>Lees, JR</creatorcontrib><creatorcontrib>Ding, Y</creatorcontrib><creatorcontrib>Bromberg, JS</creatorcontrib><title>Immunobiology of Transplantation: Impact on Targets for Large and Small Molecules</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Organ transplantation is the preferred method of treatment for many forms of end‐stage organ failure. However, immunosuppressive drugs that are used to avoid rejection can result in numerous undesirable effects (infection, malignancy, hypertension, diabetes, and accelerated arteriosclerosis). Moreover, they are not effective at preventing chronic rejection resulting in late graft loss. This review summarizes the fundamental concepts underlying the rejection of solid‐organ allografts with the aim of highlighting potential new targets for therapeutics. Future improvement will depend on new therapeutic moieties, including biologics, to target various pathways of both the innate and adaptive arms of immunity. Results from some of the most recent clinical trials in transplantation and emerging new therapies are also discussed.
Clinical Pharmacology & Therapeutics (2011) 90 2, 229–242. doi:10.1038/clpt.2011.106</description><subject>Adaptive Immunity</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Drug Delivery Systems</subject><subject>Drug Design</subject><subject>Graft Rejection - immunology</subject><subject>Graft Rejection - prevention & control</subject><subject>Graft Survival - drug effects</subject><subject>Graft Survival - immunology</subject><subject>Humans</subject><subject>Immunity, Innate</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Medical sciences</subject><subject>Organ Transplantation - methods</subject><subject>Pharmacology. Drug treatments</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1P3DAYhK2KCpaPY6-VOSBOAdvJeu3e0AroSlsBanqO3nVeo1ROnNqJ0P77OspCbz3ZIz0zHg8hXzi74SxXt8b1w41gnCcpP5EFX-Yik8t8eUQWjDGdaZHLE3Ia4-8kC63UMTkRfMWlWMkFedm07dj5XeOdf91Tb2kZoIu9g26AofHdN7ppezAD9R0tIbziEKn1gW6nO4Wupj9bcI7-8A7N6DCek88WXMSLw3lGfj3cl-vv2fbpcbO-22Ym10pmICUHITgTykKtJCtqxbUwqNnUTO5srQA1Z6gtKqy5kaqoNd_lyAsLMj8j13NuH_yfEeNQtU006FJz9GOslFIs_Z2rRGYzaYKPMaCt-tC0EPYVZ9U0YjWNWE0jJjklfz0kj7sW6w_6fbUEXB0AiAacTYuZJv7jioKtZJEnTs_cW-Nw__9Xq_Vzud4-l5OeS1zO3g6GMeCHeTK9M38Bbz-W-g</recordid><startdate>201108</startdate><enddate>201108</enddate><creator>Azimzadeh, AM</creator><creator>Lees, JR</creator><creator>Ding, Y</creator><creator>Bromberg, JS</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201108</creationdate><title>Immunobiology of Transplantation: Impact on Targets for Large and Small Molecules</title><author>Azimzadeh, AM ; Lees, JR ; Ding, Y ; Bromberg, JS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3986-a661a221028fad8604d8192ce9062766bfd8ae910e9fe8ed1c684d91b3e14fa63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adaptive Immunity</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Drug Delivery Systems</topic><topic>Drug Design</topic><topic>Graft Rejection - immunology</topic><topic>Graft Rejection - prevention & control</topic><topic>Graft Survival - drug effects</topic><topic>Graft Survival - immunology</topic><topic>Humans</topic><topic>Immunity, Innate</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Medical sciences</topic><topic>Organ Transplantation - methods</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Azimzadeh, AM</creatorcontrib><creatorcontrib>Lees, JR</creatorcontrib><creatorcontrib>Ding, Y</creatorcontrib><creatorcontrib>Bromberg, JS</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Azimzadeh, AM</au><au>Lees, JR</au><au>Ding, Y</au><au>Bromberg, JS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunobiology of Transplantation: Impact on Targets for Large and Small Molecules</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2011-08</date><risdate>2011</risdate><volume>90</volume><issue>2</issue><spage>229</spage><epage>242</epage><pages>229-242</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><coden>CLPTAT</coden><abstract>Organ transplantation is the preferred method of treatment for many forms of end‐stage organ failure. However, immunosuppressive drugs that are used to avoid rejection can result in numerous undesirable effects (infection, malignancy, hypertension, diabetes, and accelerated arteriosclerosis). Moreover, they are not effective at preventing chronic rejection resulting in late graft loss. This review summarizes the fundamental concepts underlying the rejection of solid‐organ allografts with the aim of highlighting potential new targets for therapeutics. Future improvement will depend on new therapeutic moieties, including biologics, to target various pathways of both the innate and adaptive arms of immunity. Results from some of the most recent clinical trials in transplantation and emerging new therapies are also discussed.
Clinical Pharmacology & Therapeutics (2011) 90 2, 229–242. doi:10.1038/clpt.2011.106</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>21716276</pmid><doi>10.1038/clpt.2011.106</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2011-08, Vol.90 (2), p.229-242 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_888092318 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adaptive Immunity Animals Biological and medical sciences Drug Delivery Systems Drug Design Graft Rejection - immunology Graft Rejection - prevention & control Graft Survival - drug effects Graft Survival - immunology Humans Immunity, Innate Immunosuppressive Agents - pharmacology Medical sciences Organ Transplantation - methods Pharmacology. Drug treatments |
| title | Immunobiology of Transplantation: Impact on Targets for Large and Small Molecules |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T01%3A54%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunobiology%20of%20Transplantation:%20Impact%20on%20Targets%20for%20Large%20and%20Small%20Molecules&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Azimzadeh,%20AM&rft.date=2011-08&rft.volume=90&rft.issue=2&rft.spage=229&rft.epage=242&rft.pages=229-242&rft.issn=0009-9236&rft.eissn=1532-6535&rft.coden=CLPTAT&rft_id=info:doi/10.1038/clpt.2011.106&rft_dat=%3Cproquest_cross%3E888092318%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=888092318&rft_id=info:pmid/21716276&rfr_iscdi=true |